Frustaci, A., Montillo, M., Rossi, D., Zinzani, P., Motta, M., Gaidano, G., et al. (2023). EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. In Supplement: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023 (pp.62-63) [10.1002/hon.3163_27].

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Cairoli R.;
2023

paper
Congresses as Topic; Humans; Lymphoma; Switzerland
English
17th International Conference on Malignant Lymphoma - 13 - 17 June, 2023
2023
Supplement: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023
2023
41
S2
62
63
none
Frustaci, A., Montillo, M., Rossi, D., Zinzani, P., Motta, M., Gaidano, G., et al. (2023). EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. In Supplement: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023 (pp.62-63) [10.1002/hon.3163_27].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/506519
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact